Fredun Pharmaceuticals Q1 FY25 PAT drops QoQ to Rs. 4.12 Cr
Fredun Pharmaceuticals has reported total income of Rs. 78.81 crores during the period ended June 30, 2024
Fredun Pharmaceuticals has reported total income of Rs. 78.81 crores during the period ended June 30, 2024
Themis Medicare has reported total income of Rs. 123.95 crores during the period ended June 30, 2024
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
Decision on EU marketing authorisation for this population expected by September 2024
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
Indoco Remedies is addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe
Campaign launched to spread awareness regarding dengue prevention and control
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Subscribe To Our Newsletter & Stay Updated